Key result
Diagnosis of AL amyloidosis in 2013-2016 showed a non-significant trend toward improved 6-month overall survival compared to 2008-2012 (78% vs. 67%; adjusted OR 2.22, 95% CI 0.88-5.56).
Why the study?
Does management in a more recent time period (2013-2016) improve overall survival in patients with AL amyloidosis compared to an earlier period (2008-2012)?
Cohort (n=126)
Yes
Does management in a more recent time period (2013-2016) improve overall survival in patients with AL amyloidosis compared to an earlier period (2008-2012)?
Odds Ratio: 2.22 (95% CI 0.88–5.56)
Absolute Event Rate: 78% vs 67%
p-value: p=0.216
Despite more advanced cardiac disease and higher bortezomib use in the recent cohort, 6-month overall survival showed only a non-significant trend toward improvement, highlighting the need for earlier diagnosis of cardiac amyloidosis.
No takes yet. Share an insight, caveat, or question.
Era-based AL amyloidosis survival trend inconclusive; hypothesis-generating and should not yet alter management.
Rutten et al. (2018) conducted a cohort in AL amyloidosis (n=126). Diagnosis in 2013-2016 vs. Diagnosis in 2008-2012 was evaluated on 6-month overall survival (adjusted OR 2.22, 95% CI 0.88-5.56, p=0.216). Diagnosis of AL amyloidosis in 2013-2016 showed a non-significant trend toward improved 6-month overall survival compared to 2008-2012 (78% vs. 67%; adjusted OR 2.22, 95% CI 0.88-5.56).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: